



August 25, 2023

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Chief Strategy Officer
Toshiya Kitagawa
(TEL. 03-6214-3600)

Frequently Asked Questions and Answers

GNI Group Ltd., (TSE Growth listed code: 2160; “the Company” or “we”) today disclosed the following questions and the answers we received from investors after our announcement of FY2023Q2 financial results on August 14, 2023, and the analyst meeting on August 17, 2023, as well as the answers to them, as follows. This disclosure is made in the interest of enhancing information disclosure and fair disclosure.

Q1: In your recent disclosure on August 16, 2023, you stated that the groundwork was laid for the listing of our subsidiary Cullgen. Will you be listing Cullgen soon?

A1: As soon as the Board of Directors makes a formal decision, we will promptly let you know.

Q2: It looks like the business results for FY2023 will be very strong; is this a one-time event?

A2: As we have not disclosed forecasts for the next fiscal year and beyond, we cannot give specific figures. With that being said, we believe that the growth will be steady and not transitory.

Q3: In your recent disclosure on August 16, 2023, the exchange rates for the full-year earnings forecast were US\$1=130.77 yen and 1 RMB = 19.38 yen. Are these rates also used in the calculation of the second-quarter results?

A3: For the second quarter financial results, the exchange rates used to prepare the income statement are US\$1 = 135.00 yen and RMB1 = 19.46 yen.

Q4: With regard to Q3, the yen has recently weakened further. When will you change your full-year figures to the current rate?

A4: We are aware that there is a large gap between the current exchange rate and the 130.77 yen that we used to calculate our full-year forecast, and we will make the change by the time the full-year results are announced while monitoring the situation.

About GNI Group Ltd.:

The Company is a holding company of global healthcare company listed on the Growth Board of the Tokyo Stock Exchange

and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below:

<https://www.gnipharma.com/>

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. ("the Company"). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.